1
|
Alavi SE, Alharthi S, Alavi SF, Alavi SZ, Zahra GE, Raza A, Ebrahimi Shahmabadi H. Microfluidics for personalized drug delivery. Drug Discov Today 2024; 29:103936. [PMID: 38428803 DOI: 10.1016/j.drudis.2024.103936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2023] [Revised: 02/15/2024] [Accepted: 02/26/2024] [Indexed: 03/03/2024]
Abstract
This review highlights the transformative impact of microfluidic technology on personalized drug delivery. Microfluidics addresses issues in traditional drug synthesis, providing precise control and scalability in nanoparticle fabrication, and microfluidic platforms show high potential for versatility, offering patient-specific dosing and real-time monitoring capabilities, all integrated into wearable technology. Covalent conjugation of antibodies to nanoparticles improves bioactivity, driving innovations in drug targeting. The integration of microfluidics with sensor technologies and artificial intelligence facilitates real-time feedback and autonomous adaptation in drug delivery systems. Key challenges, such as droplet polydispersity and fluidic handling, along with future directions focusing on scalability and reliability, are essential considerations in advancing microfluidics for personalized drug delivery.
Collapse
Affiliation(s)
- Seyed Ebrahim Alavi
- School of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4215, Australia.
| | - Sitah Alharthi
- Department of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Al-Dawadmi Campus, Al-Dawadmi 11961, Saudi Arabia
| | - Seyedeh Fatemeh Alavi
- State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering, Fujian Provincial Key Laboratory of Theoretical and Computational Chemistry, and Innovation Laboratory for Sciences and Technologies of Energy Materials of Fujian Province (IKKEM), Xiamen University, Xiamen, Fujian 361005, PR China
| | - Seyed Zeinab Alavi
- Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan 7718175911, Iran
| | - Gull E Zahra
- Government College University Faisalabad, Faisalabad, Pakistan
| | - Aun Raza
- School of Pharmacy, Fudan University, Shanghai 201203, PR China
| | - Hasan Ebrahimi Shahmabadi
- Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan 7718175911, Iran.
| |
Collapse
|
2
|
Elbadawi M, Li H, Basit AW, Gaisford S. The role of artificial intelligence in generating original scientific research. Int J Pharm 2024; 652:123741. [PMID: 38181989 DOI: 10.1016/j.ijpharm.2023.123741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 12/20/2023] [Accepted: 12/22/2023] [Indexed: 01/07/2024]
Abstract
Artificial intelligence (AI) is a revolutionary technology that is finding wide application across numerous sectors. Large language models (LLMs) are an emerging subset technology of AI and have been developed to communicate using human languages. At their core, LLMs are trained with vast amounts of information extracted from the internet, including text and images. Their ability to create human-like, expert text in almost any subject means they are increasingly being used as an aid to presentation, particularly in scientific writing. However, we wondered whether LLMs could go further, generating original scientific research and preparing the results for publication. We taskedGPT-4, an LLM, to write an original pharmaceutics manuscript, on a topic that is itself novel. It was able to conceive a research hypothesis, define an experimental protocol, produce photo-realistic images of 3D printed tablets, generate believable analytical data from a range of instruments and write a convincing publication-ready manuscript with evidence of critical interpretation. The model achieved all this is less than 1 h. Moreover, the generated data were multi-modal in nature, including thermal analyses, vibrational spectroscopy and dissolution testing, demonstrating multi-disciplinary expertise in the LLM. One area in which the model failed, however, was in referencing to the literature. Since the generated experimental results appeared believable though, we suggest that LLMs could certainly play a role in scientific research but with human input, interpretation and data validation. We discuss the potential benefits and current bottlenecks for realising this ambition here.
Collapse
Affiliation(s)
- Moe Elbadawi
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.
| | - Hanxiang Li
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| | - Abdul W Basit
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| | - Simon Gaisford
- UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.
| |
Collapse
|
3
|
Chen C, Chen Z, Luo W, Xu Y, Yang S, Yang G, Chen X, Chi X, Xie N, Zeng Z. Ethical perspective on AI hazards to humans: A review. Medicine (Baltimore) 2023; 102:e36163. [PMID: 38050218 PMCID: PMC10695628 DOI: 10.1097/md.0000000000036163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Accepted: 10/26/2023] [Indexed: 12/06/2023] Open
Abstract
This article explores the potential ethical hazards of artificial intelligence (AI) on society from an ethical perspective. We introduce the development and application of AI, emphasizing its potential benefits and possible negative impacts. We particularly examine the application of AI in the medical field and related ethical and legal issues, and analyze potential hazards that may exist in other areas of application, such as autonomous driving, finance, and security. Finally, we offer recommendations to help policymakers, technology companies, and society as a whole address the potential hazards of AI. These recommendations include strengthening regulation and supervision of AI, increasing public understanding and awareness of AI, and actively exploring how to use the advantages of AI to achieve a more just, equal, and sustainable social development. Only by actively exploring the advantages of AI while avoiding its negative impacts can we better respond to future challenges.
Collapse
Affiliation(s)
- Changye Chen
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| | - Ziyu Chen
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| | - Wenyu Luo
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
- The School of Public Health, Guilin Medical University, Gui Lin, Guangxi, China
| | - Ying Xu
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| | - Sixia Yang
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| | - Guozhao Yang
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| | - Xuhong Chen
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| | - Xiaoxia Chi
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| | - Ni Xie
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| | - Zhuoying Zeng
- The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, Guangdong, China
| |
Collapse
|
4
|
Malheiro V, Duarte J, Veiga F, Mascarenhas-Melo F. Exploiting Pharma 4.0 Technologies in the Non-Biological Complex Drugs Manufacturing: Innovations and Implications. Pharmaceutics 2023; 15:2545. [PMID: 38004525 PMCID: PMC10674941 DOI: 10.3390/pharmaceutics15112545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2023] [Revised: 10/15/2023] [Accepted: 10/23/2023] [Indexed: 11/26/2023] Open
Abstract
The pharmaceutical industry has entered an era of transformation with the emergence of Pharma 4.0, which leverages cutting-edge technologies in manufacturing processes. These hold tremendous potential for enhancing the overall efficiency, safety, and quality of non-biological complex drugs (NBCDs), a category of pharmaceutical products that pose unique challenges due to their intricate composition and complex manufacturing requirements. This review attempts to provide insight into the application of select Pharma 4.0 technologies, namely machine learning, in silico modeling, and 3D printing, in the manufacturing process of NBCDs. Specifically, it reviews the impact of these tools on NBCDs such as liposomes, polymeric micelles, glatiramer acetate, iron carbohydrate complexes, and nanocrystals. It also addresses regulatory challenges associated with the implementation of these technologies and presents potential future perspectives, highlighting the incorporation of digital twins in this field of research as it seems to be a very promising approach, namely for the optimization of NBCDs manufacturing processes.
Collapse
Affiliation(s)
- Vera Malheiro
- Drug Development and Technology Laboratory, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; (V.M.); (J.D.); (F.V.)
| | - Joana Duarte
- Drug Development and Technology Laboratory, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; (V.M.); (J.D.); (F.V.)
| | - Francisco Veiga
- Drug Development and Technology Laboratory, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; (V.M.); (J.D.); (F.V.)
- LAQV, REQUIMTE, Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
| | - Filipa Mascarenhas-Melo
- Drug Development and Technology Laboratory, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; (V.M.); (J.D.); (F.V.)
- LAQV, REQUIMTE, Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
- Higher School of Health, Polytechnic Institute of Guarda, Rua da Cadeia, 6300-307 Guarda, Portugal
| |
Collapse
|